These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies. Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781 [TBL] [Abstract][Full Text] [Related]
4. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery. Sørensen K; Stjern HE; Karlsen BAG; Tomter G; Ystad I; Herud I; Baevre MS; Llohn AH; Akkök ÇA Acta Obstet Gynecol Scand; 2022 Apr; 101(4):431-440. PubMed ID: 35224728 [TBL] [Abstract][Full Text] [Related]
6. Costs and benefits of non-invasive fetal RhD determination. Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024 [TBL] [Abstract][Full Text] [Related]
7. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland. Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women. Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I; BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830 [TBL] [Abstract][Full Text] [Related]
9. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients. Ben-David G; Sheiner E; Levy A; Erez O; Mazor M J Matern Fetal Neonatal Med; 2008 Apr; 21(4):255-9. PubMed ID: 18330822 [TBL] [Abstract][Full Text] [Related]
10. [Guideline for prevention of RhD alloimmunization in RhD negative women]. Lubuský M; Procházka M; Simetka O; Holusková I Ceska Gynekol; 2010 Aug; 75(4):323-4. PubMed ID: 20925231 [TBL] [Abstract][Full Text] [Related]
11. [Guideline for prevention of RhD alloimmunizationin RhD negative women]. Lubušký M; Procházka M; Simetka O; Holusková I Ceska Gynekol; 2013 Apr; 78(2):132-3. PubMed ID: 23710977 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis. Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771 [TBL] [Abstract][Full Text] [Related]
14. Prevention of RhD alloimmunization in RhD negative women. Lubusky M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Mar; 154(1):3-7. PubMed ID: 20445704 [TBL] [Abstract][Full Text] [Related]
16. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334 [TBL] [Abstract][Full Text] [Related]
17. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602 [TBL] [Abstract][Full Text] [Related]